Skip to Main Content

Author Details

Francois Pognan
Novartis
1988
53
23
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36644817Incorporating microglia-like cells in human induced pluripotent stem cell-derived retinal organoids.J Cell Mol Med2023
37316648eTRANSAFE: data science to empower translational safety assessment.Nat Rev Drug Discov2023
37439009Neurofilament Light Chain: A Translational Safety Biomarker for Drug-Induced Peripheral Neurotoxicity.Toxicol Pathol2023
36781957The evolving role of investigative toxicology in the pharmaceutical industry.Nat Rev Drug Discov2023
35298655Human Retinal Organoids Provide a Suitable Tool for Toxicological Investigations: A Comprehensive Validation Using Drugs and Compounds Affecting the Retina.Stem Cells Transl Med2022
36353522Liver enzyme delayed clearance in rat treated by CSF1 receptor specific antagonist Sotuletinib.Curr Res Toxicol2022
34326236Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2.Science2021
33791693Phospholipidosis is a shared mechanism underlying the in vitro antiviral activity of many repurposed drugs against SARS-CoV-2.bioRxiv2021
33637997Guidelines for FAIR sharing of preclinical safety and off-target pharmacology data.ALTEX2021
33800393The eTRANSAFE Project on Translational Safety Assessment through Integrative Knowledge Management: Achievements and Perspectives.Pharmaceuticals (Basel)2021
32242633Introducing the concept of virtual control groups into preclinical toxicology testing.ALTEX2020
30570669Optimizing drug discovery by Investigative Toxicology: Current and future trends.ALTEX2019
30894455Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes.J Pharmacol Exp Ther2019
29316298Improving the Safety Assessment of Chemicals and Drug Candidates by the Integration of Bioinformatics and Chemoinformatics Data.Basic Clin Pharmacol Toxicol2018
29432567Bile Acid Sequestration by Cholestyramine Mitigates FGFR4 Inhibition-Induced ALT Elevation.Toxicol Sci2018
29556671Induction of hemangiosarcoma in mice after chronic treatment with S1P-modulator siponimod and its lack of relevance to rat and human.Arch Toxicol2018
27742868Editor's Highlight: Comparative Renal Safety Assessment of the Hepatitis B Drugs, Adefovir, Tenofovir, Telbivudine and Entecavir in Rats.Toxicol Sci2017
29026211Legacy data sharing to improve drug safety assessment: the eTOX project.Nat Rev Drug Discov2017
27923774Mechanistic insights into selective killing of OXPHOS-dependent cancer cells by arctigenin.Toxicol In Vitro2017
27605099OntoBrowser: a collaborative tool for curation of ontologies by subject matter experts.Bioinformatics2017
26874804Bile acids in drug induced liver injury: Key players and surrogate markers.Clin Res Hepatol Gastroenterol2016
27689095Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans.Biomed Res Int2016
24933330Determination of liver specific toxicities in rat hepatocytes by high content imaging during 2-week multiple treatment.Toxicol In Vitro2015
25630683Reduced Activity of Sphingosine-1-Phosphate Lyase Induces Podocyte-related Glomerular Proteinuria, Skin Irritation, and Platelet Activation.Toxicol Pathol2015
25794480Ensuring confidence in predictions: A scheme to assess the scientific validity of in silico models.Adv Drug Deliv Rev2015
25339109Phase II metabolism in human skin: skin explants show full coverage for glucuronidation, sulfation, N-acetylation, catechol methylation, and glutathione conjugation.Drug Metab Dispos2015
25249692Aldehyde oxidase activity in fresh human skin.Drug Metab Dispos2014
25405742The eTOX data-sharing project to advance in silico drug-induced toxicity prediction.Int J Mol Sci2014
22193206The use of rat lens explant cultures to study the mechanism of drug-induced cataractogenesis.Toxicol Sci2012
22769724Investigative safety science as a competitive advantage for Pharma.Expert Opin Drug Metab Toxicol2012
22859947Perturbation of microRNAs in rat heart during chronic doxorubicin treatment.PLoS One2012
22489185Inroads to predict in vivo toxicology-an introduction to the eTOX Project.Int J Mol Sci2012
21129774Preclinical evaluation of potential nilotinib cardiotoxicity.Leuk Res2011
21653914Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics.Int J Toxicol2011
20122731Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies.Leuk Res2010
19157065Mapping the epigenome--impact for toxicology.EXS2009
18539914Mechanistic investigation of N,N-diethyl-4-(phenyl-piperidin-4-ylidenemethyl)-benzamide-induced insulin depletion in the rat and RINm5F cells.Toxicol Sci2008
17195477Toxicogenomics applied to predictive and exploratory toxicology for the safety assessment of new chemical entities: a long road with deep potholes.Prog Drug Res2007
16463016Validation of an in vitro screen for phospholipidosis using a high-content biology platform.Cell Biol Toxicol2006
15030884Integrated application of transcriptomics and metabonomics yields new insight into the toxicity due to paracetamol in the mouse.J Pharm Biomed Anal2004
15469409Genomics, proteomics and metabonomics in toxicology: hopefully not 'fashionomics'.Pharmacogenomics2004
15319485Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation.Toxicol Sci2004
12641429An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy.Chem Res Toxicol2003
12689424In utero transmission of Encephalitozoon cuniculi strain type I in rabbits.Lab Anim2003
11752693Genomics and proteomics analysis of acetaminophen toxicity in mouse liver.Toxicol Sci2002
11680884Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology.Proteomics2001
10951200Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity.Eur J Biochem2000
9352123Establishment of a rat Sertoli cell line that displays the morphological and some of the functional characteristics of the native cell.Cell Biol Toxicol1997
7932579Synthesis and structure-activity relationship of methyl-substituted indolo[2,3-b]quinolines: novel cytotoxic, DNA topoisomerase II inhibitors.J Med Chem1994
1335251A carboline derivative as a novel mammalian DNA topoisomerase II targeting agent.Biochem Pharmacol1992
  • 1 - 50 of 53

Recommended Authors

Center for Drug Evaluations and Research (CDER)
Career Start Year 2013
Number of shared co-authors 0
Centre Hospitalier Universitaire Sainte-Justine Research Centre
Career Start Year 2011
Number of shared co-authors 0
INSERM UMR-S1124, Universite Paris Cite
Career Start Year 2005
Number of shared co-authors 0
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade
Career Start Year 2004
Number of shared co-authors 0
National Center for Advancing Translational Sciences, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 3
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2001
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute
Career Start Year 2001
Number of shared co-authors 2
SAS Institute Inc Cary
Career Start Year 2000
Number of shared co-authors 0
National Institute of Environmental Health Sciences
Career Start Year 2000
Number of shared co-authors 1
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences
Career Start Year 1998
Number of shared co-authors 0
Columbia University
Career Start Year 1998
Number of shared co-authors 0
and of Biochemistry and Pharmacy, University of Tuebingen
Career Start Year 1996
Number of shared co-authors 0
Joint Research Centre (JRC)
Career Start Year 1996
Number of shared co-authors 0
Syntimmune Inc.
Career Start Year 1995
Number of shared co-authors 0
National Center for Advancing Translational Sciences, National Institutes of Health
Career Start Year 1994
Number of shared co-authors 0
F. Hoffmann-La Roche Ltd
Career Start Year 1993
Number of shared co-authors 0
The University of Danang-University of Science and Technology
Career Start Year 1993
Number of shared co-authors 0
National Center for Toxicological Research
Career Start Year 1992
Number of shared co-authors 2
National Institutes of Health, National Center for Advancing Translational Sciences
Career Start Year 1992
Number of shared co-authors 0
St. George's University Medical School
Career Start Year 1990
Number of shared co-authors 3
Departamento de Toxicologia y Farmacologia Preclinica
Career Start Year 1989
Number of shared co-authors 8
Institute of Pharmacy and Molecular Biotechnology, Heidelberg University
Career Start Year 1987
Number of shared co-authors 0
Philip Morris International Research Laboratories Pte. Ltd
Career Start Year 1987
Number of shared co-authors 2
Maastricht University
Career Start Year 1981
Number of shared co-authors 7
National Institute of Environmental Health Sciences
Career Start Year 1980
Number of shared co-authors 0
Institute of Biomedical Engineering (IBME), University of Oxford
Career Start Year 1976
Number of shared co-authors 0
The Institute of Cancer Research
Career Start Year 1974
Number of shared co-authors 2
PHusis Therapeutics Inc.
Career Start Year 1970
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1968
Number of shared co-authors 2
Institute of Biophysics of the Czech Academy of Sciences
Career Start Year 1962
Number of shared co-authors 0

Collaborators

Co-authored papers 7
Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University
Co-authored papers 5
Novartis Institutes for BioMedical Research, Novartis Pharma AG
Co-authored papers 4
Erasmus Medical Center
Co-authored papers 3
Erasmus University Medical Center
Co-authored papers 3
Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra
Co-authored papers 3
Erasmus MC - University Medical Center Rotterdam
Co-authored papers 3
Department of Preclinical Safety, Novartis Institutes for BioMedical Research
Co-authored papers 3
Novo Nordisk Foundation Center for Protein Research, University of Copenhagen
Co-authored papers 2
Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG)
Co-authored papers 2
University of Michigan ann arbor
Co-authored papers 2
University Medical Center Hamburg-Eppendorf
Co-authored papers 2
Icahn School of Medicine at Mount Sinai
Co-authored papers 2
Institut Pasteur, Center for the Viral Populations and Pathogenesis
Co-authored papers 2
Department of Pharmaceutical Chemistry, University of California san francisco
Co-authored papers 2
Blavatnik Institute, Harvard Medical School
Co-authored papers 2
Institut Pasteur, CNRS UMR 3569
Co-authored papers 2
Josep Carreras Leukaemia Research Institute (IJC)
Co-authored papers 2
Department of Pharmaceutical Chemistry, University of California san francisco
Co-authored papers 2
Matrahaza University and Teaching Hospital
Co-authored papers 2
Harvard Medical School
Co-authored papers 2
University of California San Francisco
Co-authored papers 2
Quantitative Biosciences Institute (QBI), University of California San Francisco
Co-authored papers 2
Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG)
Co-authored papers 2
Preclinical Safety, Novartis Institutes for Biomedical Research
Co-authored papers 2
Hospital del Mar Medical Research Institute
Co-authored papers 2
Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG)
Co-authored papers 2
Spanish National Bioinformatics Institute (INB/ELIXIR-ES)
Co-authored papers 2
University of California San Francisco
Co-authored papers 2
Universitat Tubingen, Institut fur Arbeitsmedizin
Co-authored papers 2